Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Market Worth In Excess Of $1bn
Executive Summary
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
You may also be interested in...
Interview: Amryt Aims High After Aegerion Acquisition
The Irish firm's CEO told Scrip about a transformative deal for Amryt, creating an international business with revenues of nearly $140m.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.